Logo image of INGN

INOGEN INC (INGN) Stock Fundamental Analysis

NASDAQ:INGN - Nasdaq - US45780L1044 - Common Stock - Currency: USD

7.04  +0.56 (+8.64%)

After market: 7.04 0 (0%)

Fundamental Rating

3

INGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of INGN is average, but there are quite some concerns on its profitability. INGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

INGN had negative earnings in the past year.
In the past year INGN has reported a negative cash flow from operations.
INGN had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: INGN reported negative operating cash flow in multiple years.
INGN Yearly Net Income VS EBIT VS OCF VS FCFINGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.91%, INGN is in the better half of the industry, outperforming 62.03% of the companies in the same industry.
INGN has a Return On Equity of -13.88%. This is in the better half of the industry: INGN outperforms 64.17% of its industry peers.
Industry RankSector Rank
ROA -8.91%
ROE -13.88%
ROIC N/A
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
INGN Yearly ROA, ROE, ROICINGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

INGN has a worse Gross Margin (46.11%) than 60.96% of its industry peers.
INGN's Gross Margin has been stable in the last couple of years.
INGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
INGN Yearly Profit, Operating, Gross MarginsINGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

6

2. Health

2.1 Basic Checks

INGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INGN has been increased compared to 1 year ago.
The number of shares outstanding for INGN has been increased compared to 5 years ago.
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INGN Yearly Shares OutstandingINGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INGN Yearly Total Debt VS Total AssetsINGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

INGN has an Altman-Z score of 1.52. This is a bad value and indicates that INGN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INGN (1.52) is comparable to the rest of the industry.
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.52
ROIC/WACCN/A
WACC8.91%
INGN Yearly LT Debt VS Equity VS FCFINGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

INGN has a Current Ratio of 3.07. This indicates that INGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.07, INGN is in line with its industry, outperforming 57.22% of the companies in the same industry.
INGN has a Quick Ratio of 2.67. This indicates that INGN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.67, INGN is doing good in the industry, outperforming 60.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.67
INGN Yearly Current Assets VS Current LiabilitesINGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.43% over the past year.
Looking at the last year, INGN shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
INGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.49% yearly.
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%3.96%

3.2 Future

The Earnings Per Share is expected to grow by 16.18% on average over the next years. This is quite good.
INGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.30% yearly.
EPS Next Y30.43%
EPS Next 2Y19.94%
EPS Next 3Y16.18%
EPS Next 5YN/A
Revenue Next Year7.3%
Revenue Next 2Y6.76%
Revenue Next 3Y6.3%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INGN Yearly Revenue VS EstimatesINGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M
INGN Yearly EPS VS EstimatesINGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INGN. In the last year negative earnings were reported.
Also next year INGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INGN Price Earnings VS Forward Price EarningsINGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INGN Per share dataINGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

A more expensive valuation may be justified as INGN's earnings are expected to grow with 16.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.94%
EPS Next 3Y16.18%

More info and screens

0

5. Dividend

5.1 Amount

INGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOGEN INC

NASDAQ:INGN (8/11/2025, 4:30:02 PM)

After market: 7.04 0 (0%)

7.04

+0.56 (+8.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners71.06%
Inst Owner Change-0.93%
Ins Owners1.93%
Ins Owner Change9.28%
Market Cap189.31M
Analysts77.78
Price Target13.26 (88.35%)
Short Float %4.17%
Short Ratio4.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.35%
Min EPS beat(2)33.97%
Max EPS beat(2)50.73%
EPS beat(4)4
Avg EPS beat(4)48%
Min EPS beat(4)33.97%
Max EPS beat(4)56.83%
EPS beat(8)6
Avg EPS beat(8)19.27%
EPS beat(12)9
Avg EPS beat(12)22.62%
EPS beat(16)11
Avg EPS beat(16)50.76%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)1.4%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)4.16%
Min Revenue beat(4)1.4%
Max Revenue beat(4)6.23%
Revenue beat(8)5
Avg Revenue beat(8)0.73%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)10
Avg Revenue beat(16)1.41%
PT rev (1m)0%
PT rev (3m)30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.9%
EPS NY rev (1m)0%
EPS NY rev (3m)25.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS12.64
BVpS7.36
TBVpS5.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.91%
ROE -13.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.11%
FCFM N/A
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
F-Score6
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.68%
Cap/Sales 4.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 2.67
Altman-Z 1.52
F-Score6
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)106.82%
Cap/Depr(5y)105.29%
Cap/Sales(3y)6.42%
Cap/Sales(5y)6.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y30.43%
EPS Next 2Y19.94%
EPS Next 3Y16.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%3.96%
Revenue Next Year7.3%
Revenue Next 2Y6.76%
Revenue Next 3Y6.3%
Revenue Next 5YN/A
EBIT growth 1Y55.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3Y29.04%
EBIT Next 5YN/A
FCF growth 1Y57.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.19%
OCF growth 3Y-36.98%
OCF growth 5Y-31.97%